JBCHEPHARM
J B CHEMICALS AND PHARMA
Each stock's 10,000-path forecast, rendered as light.
J B CHEMICALS AND PHARMA (JBCHEPHARM) Stock Analysis & Case Study
Is JBCHEPHARM a good buy? The data-driven verdict.
J B CHEMICALS AND PHARMA (JBCHEPHARM) trades at ₹2,206,on the numbers it worth a closer look, a Downstox Snapshot Score of 60/100.
On the numbers, J B CHEMICALS AND PHARMA (JBCHEPHARM) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 49.4× earnings, ROE of 18.9%, a 63% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
JBCHEPHARM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is JBCHEPHARM overvalued? JBCHEPHARM P/E vs its sector
JBCHEPHARM's P/E of 49.4× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 1.00% dividend yield is below the peer median of 1.65%.
JBCHEPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of JBCHEPHARM history (11%/yr drift, 26%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| JBCHEPHARM 2027 | ₹1,718 | ₹2,385 | ₹3,303 | +9% |
| JBCHEPHARM 2028 | ₹1,619 | ₹2,588 | ₹4,129 | +18% |
| JBCHEPHARM 2029 | ₹1,576 | ₹2,807 | ₹4,976 | +28% |
| JBCHEPHARM 2030 | ₹1,569 | ₹3,047 | ₹5,902 | +39% |
| JBCHEPHARM 2031 | ₹1,575 | ₹3,286 | ₹6,965 | +50% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability JBCHEPHARM goes up, or doubles?
The bull case for JBCHEPHARM
- High return on equity (18.9%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (25.4%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹2,385 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,976.
The bear case & risks
- A rich 49.4× P/E leaves a thin margin of safety if growth slows.
- A steep 8.5× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,576.
JBCHEPHARM volatility & expected range, how bumpy is the ride?
Over the last 2.0 years JBCHEPHARM compounded at 11%/year with annualized volatility of 26%. That volatility implies a 1-year 80% range of ₹1,718–₹3,303, the honest backbone behind any single price target.
JBCHEPHARM price forecast, the full 60-month probability fan
JBCHEPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds JBCHEPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the JBCHEPHARM price target & forecast page.
JBCHEPHARM Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. JBCHEPHARM scores 4/9,mixed financial health.
JBCHEPHARM MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy JBCHEPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 27.1% | 3.7× |
| ZerodhaCHEAPEST | 27.1% | 3.7× |
| DhanCHEAPEST | 27.1% | 3.7× |
Compare every broker on the JBCHEPHARM MTF page.
JBCHEPHARM vs peers,sector comparison
About J B CHEMICALS AND PHARMA: sector, index & market-cap context
J B CHEMICALS AND PHARMA (JBCHEPHARM) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹35,490 Cr. See more Nifty 100 stocks.
How the JBCHEPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of J B CHEMICALS AND PHARMA's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
JBCHEPHARM analysis, FAQs
Is J B CHEMICALS AND PHARMA (JBCHEPHARM) a good buy?
On the numbers, J B CHEMICALS AND PHARMA (JBCHEPHARM) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 49.4× earnings, ROE of 18.9%, a 63% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is JBCHEPHARM overvalued or undervalued?
JBCHEPHARM trades at 49.4× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the JBCHEPHARM share price target for 2031?
JBCHEPHARM's probability-weighted 2031 median target is ₹3,286, with an 80% range of ₹1,575–₹6,965 (10,000-path Monte-Carlo).
What is the probability JBCHEPHARM doubles in 5 years?
The modelled probability of JBCHEPHARM reaching ₹4,387 (2×) within 5 years is 31%.
What is the bull case for JBCHEPHARM?
High return on equity (18.9%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (25.4%) shows the core business earns well above its cost of capital. A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹2,385 (+9%).
What are the risks in JBCHEPHARM?
A rich 49.4× P/E leaves a thin margin of safety if growth slows. A steep 8.5× price-to-book means most of the value is intangible/expectations, not assets on the books.